From: Parvovirus B19 infection and severe anaemia in Kenyan children: a retrospective case control study
Months of age | IgM positive | IgG positive | ||||
---|---|---|---|---|---|---|
Cases | Controls | Overall | Cases | Controls | Overall | |
0-6 | 1/47 (2.1%) | 0/40 (0%) | 1/87 (1.1%) | 7/43 (16.3%) | 10/37 (27.0%) | 17/80 (21.3%) |
7-12 | 1/62 (1.6%) | 0/68 (0%) | 1/130 (0.8%) | 6/57 (10.5%) | 2/57 (3.5%) | 8/114 (7.0%) |
13-18 | 0/47 (0%) | 2/43 (4.7%) | 2/90 (2.2%) | 2/39 (5.1%) | 5/38 (13.2%) | 7/77 (9.0%) |
19-24 | 2/37 (5.4%) | 1/32 (3.1%) | 3/69 (4.3%) | 6/29 (20.7%) | 2/26 (7.7%) | 8/55 (14.5%) |
25-30 | 2/36 (5.6%) | 0/40 (0%) | 2/76 (2.6%) | 6/29 (20.7%) | 3/34 (8.8%) | 9/63 (14.3%) |
31-36 | 1/21 (4.8%) | 0/20 (0%) | 1/41 (2.4%) | 1/20 (5.0%) | 1/19 (5.3%) | 2/39 (5.1%) |
37-42 | 2/17 (11.8%) | 0/20 (0%) | 2/37 (5.4%) | 4/17 (23.5%) | 5/19 (26.3%) | 9/36 (25%) |
43-48 | 1/16 (6.3%) | 2/12 (16.7%) | 3/28 (10.7%) | 3/15 (20%) | 2/12 (16.7%) | 5/27 (18.5%) |
49-54 | 0/7 (0%) | 0/9 (0%) | 0/16 (0%) | 0/6 (0%) | 4/7 (57.1%) | 4/13 (30.8%) |
55-60 | 0/6 (0%) | 1/5 (20%) | 1/11 (9.1%) | 2/5 (40%) | 2/5 (40%) | 4/10 (40%) |
61-66 | 1/12 (8.3%) | 0/10 (0%) | 1/22 (4.5%) | 4/12 (33.3%) | 1/9 (11.1%) | 5/21 (23.8%) |
Total | 11/308 (3.6%) | 6/299 (2.0%) | 17/607 (2.8%) | 41/272 (15.1%) | 37/263 (14.1%) | 78/535 (14.6%) |